Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$560.24
-0.5%
$567.54
$457.42
$678.21
$34.21B0.37333,066 shs248,404 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$56.80
-3.7%
$42.52
$30.04
$63.68
$4.91B1.821.95 million shs2.88 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$48.13
-0.9%
$45.37
$37.63
$49.30
$10.70B0.681.22 million shs2.42 million shs
Repligen Corporation stock logo
RGEN
Repligen
$130.19
-2.8%
$125.65
$102.97
$182.52
$7.31B1.11727,301 shs757,950 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$54.14
-0.5%
$50.22
$46.01
$83.62
$8.49B1.391.47 million shs1.42 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
0.00%+3.11%-4.52%-3.56%+19.91%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.00%+8.91%+37.60%+44.53%+2.23%
Qiagen N.V. stock logo
QGEN
Qiagen
0.00%-0.43%+1.58%+14.66%+20.66%
Repligen Corporation stock logo
RGEN
Repligen
0.00%+2.22%-0.85%+5.97%+7.64%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%+1.89%+5.07%+6.74%-24.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenex SE stock logo
ARGX
argenex
4.414 of 5 stars
4.53.00.00.03.31.72.5
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
3.2405 of 5 stars
4.31.00.00.03.12.50.6
Qiagen N.V. stock logo
QGEN
Qiagen
3.5759 of 5 stars
1.24.01.74.51.51.71.3
Repligen Corporation stock logo
RGEN
Repligen
4.6023 of 5 stars
4.31.00.04.51.61.71.9
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.8898 of 5 stars
4.33.01.74.22.11.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
3.10
Buy$728.0629.96% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.53
Moderate Buy$71.7526.32% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.30
Hold$49.402.64% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.69
Moderate Buy$170.7531.15% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.50
Moderate Buy$70.0029.29% Upside

Current Analyst Ratings Breakdown

Latest TECH, CRSP, ARGX, QGEN, and RGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$90.00 ➝ $75.00
7/9/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
7/8/2025
argenex SE stock logo
ARGX
argenex
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
7/8/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
7/8/2025
Repligen Corporation stock logo
RGEN
Repligen
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$140.00 ➝ $130.00
7/3/2025
argenex SE stock logo
ARGX
argenex
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$700.00
7/1/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$86.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$2.25B15.19$2.97 per share188.60$90.49 per share6.19
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.31M131.47N/AN/A$22.64 per share2.51
Qiagen N.V. stock logo
QGEN
Qiagen
$2.00B5.34$3.20 per share15.02$16.05 per share3.00
Repligen Corporation stock logo
RGEN
Repligen
$634.44M11.53$3.11 per share41.90$35.21 per share3.70
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B7.32$2.31 per share23.40$13.13 per share4.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$833.04M$16.2134.5651.641.0340.20%16.15%14.33%7/24/2025 (Estimated)
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$0.40120.6719.572.454.68%14.61%8.80%8/5/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.45N/A55.173.73-3.93%4.53%3.17%7/29/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8266.0327.482.5710.89%13.17%10.17%8/6/2025 (Estimated)

Latest TECH, CRSP, ARGX, QGEN, and RGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q4 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.49N/AN/AN/A$315.14 millionN/A
8/5/2025Q2 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60N/AN/AN/A$523.97 millionN/A
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.54N/AN/AN/A$6.44 millionN/A
7/29/2025Q2 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.40N/AN/AN/A$174.62 millionN/A
7/24/2025Q2 2025
argenex SE stock logo
ARGX
argenex
$2.87N/AN/AN/A$776.82 millionN/A
5/8/2025Q1 2025
argenex SE stock logo
ARGX
argenex
$2.32$2.58+$0.26$2.58$748.34 million$1.35 billion
5/7/2025Q1 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
5/6/2025Q1 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.27-$1.58-$0.31-$1.58N/AN/A
4/29/2025Q1 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%N/A62.50%N/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.59%N/A39.02%N/A

Latest TECH, CRSP, ARGX, QGEN, and RGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%7/2/20257/3/20257/10/2025
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
7.29
6.68
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
15.64
15.64
Qiagen N.V. stock logo
QGEN
Qiagen
0.40
3.37
2.83
Repligen Corporation stock logo
RGEN
Repligen
0.27
6.79
5.79
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Repligen Corporation stock logo
RGEN
Repligen
97.64%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.30%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,59961.06 million59.58 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46086.36 million82.65 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.18 million55.51 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$560.24 -3.07 (-0.54%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$560.62 +0.38 (+0.07%)
As of 07/11/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$56.80 -2.20 (-3.73%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$56.40 -0.39 (-0.70%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Qiagen stock logo

Qiagen NYSE:QGEN

$48.13 -0.42 (-0.87%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$48.12 -0.01 (-0.02%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen stock logo

Repligen NASDAQ:RGEN

$130.19 -3.81 (-2.84%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$130.30 +0.12 (+0.09%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$54.14 -0.27 (-0.50%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$53.75 -0.39 (-0.72%)
As of 07/11/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.